ANTHEM BIOSCIENCES Results Analysis-Q4FY26

$ANTHEM Operating Revenue (highest-ever revenue quarter) for Q4FY26 is Rs. 611 Crs. 26.44% growth YoY, Total Income is Rs. 662 Crs., 33.16% growth YoY, Gross Profit is Rs. 395 Crs., 29.09% growth YoY, EBITDA is Rs. 318 Crs., 52.18% growth YoY, EBITDA Margin is 48.09% improved by 601 Basis points YoY, PBT Rs. 278 Crs. 55.86% growth YoY, PAT Rs. 190 Crs. 129.68% growth YoY. On QoQ basis Op. Revenue is up by 44.38%, Total Income is up by 44.99%, Gross Profit is up by 40.96%, EBITDA is up by 66.96%, PBT is up by 113% and PAT is also up by 104.44%. CRDMO Segment Revenue for Q4FY26 is Rs. 513 Crs. 30.72% growth YoY and 53.9% growth QoQ. Of the 4 molecules that turned commercial in FY26: 1 with big pharma, 3 with emerging biotech, Current contribution from these 4 new launches: ~8–9% of revenues, with management emphasizing “a lot of headroom to grow.” FY26 notable change: two “direct” big pharma relationships added, now “growing healthily.” Backward integration completed for a key intermediate, underpinning structurally higher gross margins into FY27. How ever margins are really, really high but company believe can maintain them and really want to grow them as well. Unit 4 Phase 1 capex plan disclosed in detail: ₹1,200 cr over FY27–FY28, with FY27 ~₹700 cr and FY28 ~₹500 cr; commissioning targeted by March 2028, doubling custom synthesis capacity and +50% fermentation capacity.